Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery ...
Trial will evaluate the safety and effectiveness of the AtriCure AtriClip® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients LeAAPS is a prospective, randomized, ...
Good afternoon, and welcome to AtriCure’s Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a ...
AtriCure recently faced a shift in analyst sentiment when JPMorgan downgraded the company to Neutral, citing rising competitive pressure on its AtriClip device from Edwards Lifesciences’ planned ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results